Patents by Inventor Vickie Brown-Driver
Vickie Brown-Driver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8298543Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.Type: GrantFiled: May 6, 2011Date of Patent: October 30, 2012Assignee: Trius Therapeutics, Inc.Inventors: Vickie Brown-Driver, Kedar GC, John M. Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
-
Publication number: 20110294774Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.Type: ApplicationFiled: May 6, 2011Publication date: December 1, 2011Applicant: TRIUS THERAPEUTICSInventors: Vickie Brown-Driver, Kedar GC, John M. Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
-
Patent number: 8021665Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.Type: GrantFiled: December 8, 2006Date of Patent: September 20, 2011Assignee: Trius Therapeutics, Inc.Inventors: Vickie Brown-Driver, Kedar GC, John M. Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
-
Publication number: 20110143359Abstract: The invention provides a method for generating and selecting drug-sensitizing antisense DNA fragments. In one embodiment, the method includes identifying a gene of interest using knowledge of bacterial physiology, biochemistry, genetics, genomics, and other means. The method includes PCR amplification of a gene of interest using genomic DNA as a template; fragmentation of the DNA by sonication or other means; selecting DNA fragments no longer than 400 base pairs; ligating the DNA fragments into a suitable expression plasmid with a selectable marker; transforming the plasmids containing the DNA fragments into the organism from which the gene of interest originated; and selecting clones from transformed cells that show a phenotypic difference of the clone grown in the presence of the inducer relative to the phenotype in the absence of inducer.Type: ApplicationFiled: February 23, 2011Publication date: June 16, 2011Inventors: Robert Haselbeck, Mark Hilgers, Karen Shaw, Vickie Brown-Driver, Kedar GC, John M. Finn, Mark Stidham
-
Patent number: 7910337Abstract: The invention provides a method for generating and selecting drug-sensitizing antisense DNA fragments. In one embodiment, the method includes identifying a gene of interest using knowledge of bacterial physiology, biochemistry, genetics, genomics, and other means. The method includes PCR amplification of a gene of interest using genomic DNA as a template; fragmentation of the DNA by sonication or other means; selecting DNA fragments no longer than 400 base pairs; ligating the DNA fragments into a suitable expression plasmid with a selectable marker; transforming the plasmids containing the DNA fragments into the organism from which the gene of interest originated; and selecting clones from transformed cells that show a phenotypic difference of the clone grown in the presence of the inducer relative to the phenotype in the absence of inducer.Type: GrantFiled: December 8, 2006Date of Patent: March 22, 2011Assignee: Trius Therapeutics, Inc.Inventors: Robert Haselbeck, Mark Hilgers, Karen Shaw, Vickie Brown-Driver, Kedar Gc, John M. Finn, Mark Stidham
-
Publication number: 20070218481Abstract: The invention provides a method for generating and selecting drug-sensitizing antisense DNA fragments. In one embodiment, the method includes identifying a gene of interest using knowledge of bacterial physiology, biochemistry, genetics, genomics, and other means. The method includes PCR amplification of a gene of interest using genomic DNA as a template; fragmentation of the DNA by sonication or other means; selecting DNA fragments no longer than 400 base pairs; ligating the DNA fragments into a suitable expression plasmid with a selectable marker; transforming the plasmids containing the DNA fragments into the organism from which the gene of interest originated; and selecting clones from transformed cells that show a phenotypic difference of the clone grown in the presence of the inducer relative to the phenotype in the absence of inducer.Type: ApplicationFiled: December 8, 2006Publication date: September 20, 2007Applicant: RX3 PHARMACEUTICALSInventors: Robert Haselbeck, Mark Hilgers, Karen Shaw, Vickie Brown-Driver, Kedar Gc, John M. Finn, Mark Stidham
-
Publication number: 20070178111Abstract: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a ?-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC, MurD, MurE, MurF, MurG, MraY, and UppS.Type: ApplicationFiled: December 8, 2006Publication date: August 2, 2007Applicant: RX3 PHARMACEUTICALSInventors: Vickie Brown-Driver, Kedar GC, John Finn, Robert Haselbeck, Mark Hilgers, Karen Shaw, Mark Stidham
-
Publication number: 20070015723Abstract: Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for viral-associated diseases and diseases associated with elevated levels of phospholipase A2 are also provided. Methods of modulating telomere length of a chromosome are also provided; modulation of telomere length is believed to play a role in the aging process of a cell and in control of malignant cell growth.Type: ApplicationFiled: May 17, 2006Publication date: January 18, 2007Inventors: Ronnie Hanecak, Kevin Anderson, C. Bennett, Ming-Yi Chiang, Vickie Brown-Driver, David Ecker, Timothy Vickers, Jacqueline Wyatt
-
Publication number: 20060154885Abstract: Compounds, compositions and methods are provided for modulating the expression of SLC26A2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SLC26A2. Methods of using these compounds for modulation of SLC26A2 expression and for diagnosis and treatment of disease associated with expression of SLC26A2 are provided.Type: ApplicationFiled: March 4, 2005Publication date: July 13, 2006Inventors: C. Bennett, Brett Monia, Nicholas Dean, Xiaoxing Xu, Sanjay Bhanot, Brenda Baker, Susan Freier, Lex Cowsert, Robert McKay, Muthiah Manoharan, F. Dorr, Jon Holmlund, Alexander Borchers, Vickie Brown-Driver, Jacqueline Wyatt, Shin Flournoy, Elizabeth Ackermann, Hong Zhang, Andrew Watt, Eric Maracusson, Scott Cooper, Erich Koller, Loren Miraglia, William Ricketts, Kenneth Dobie, Tamara Sipes
-
Publication number: 20050261228Abstract: Compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p35 subunit. The compositions comprise chemically modified antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p35 subunit. Methods of using these compounds for modulation of Interleukin 12 p35 subunit expression and for treatment of diseases associated with expression of Interleukin 12 p35 subunit are provided.Type: ApplicationFiled: March 23, 2005Publication date: November 24, 2005Inventors: C. Bennett, Brenda Baker, Susan Freier, Susan Gregory, Ronnie Hanecak, Kevin Anderson, Ming-Yi Chiang, Vickie Brown-Driver, David Ecker, Timothy Vickers, Jacqueline Wyatt, Eric Marcusson, Nicholas Dean, Sanjay Bhanot, Elizabeth Ackermann, Lex Cowsert
-
Publication number: 20050244869Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.Type: ApplicationFiled: April 1, 2005Publication date: November 3, 2005Inventors: Vickie Brown-Driver, Ravi Jain
-
Publication number: 20050026857Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of breast cancer-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding breast cancer-1. Methods of using these compounds for modulation of breast cancer-1 expression and for treatment of diseases associated with expression of breast cancer-1 are provided.Type: ApplicationFiled: August 12, 2003Publication date: February 3, 2005Inventors: Vickie Brown-Driver, Kenneth Dobie
-
Patent number: 5698391Abstract: Methods useful for the determination of oligomers which have specific activity for a target molecule from a pool of primarily randomly assembled oligomers are provided. The disclosed methods involve repeated syntheses of increasingly simplified sets of oligomers coupled with selection procedures for determining oligomers having the highest activity. Freedom from the use of enzymes allows the application of these methods to any molecules which can be oligomerized in a controlled fashion.Type: GrantFiled: December 16, 1994Date of Patent: December 16, 1997Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, David J. Ecker, Jacqueline Wyatt, Thomas W. Bruice, Kevin Anderson, Ronnie Hanecak, Timothy Vickers, Peter Davis, Susan M. Freier, Yogesh S. Sanghvi, Vickie Brown-Driver